Montevarchi

Researchers are evaluating the EuroHeart program, an observational and prospective multicenter initiative designed to improve quality of care for patients with common cardiovascular diseases such as Acute Coronary Syndrome ACS, heart failure, and atrial fibrillation. EuroHeart collects standardized and harmonized patient data to support continuous quality improvement by monitoring adherence to quality indicators defined by the European Society of Cardiology ESC. The program aims to understand how well proven treatments are applied in everyday clinical practice. The study involves continuous data collection from consecutive patients hospitalized or treated for these cardiovascular conditions. Participants enter a 12-month follow-up period during which clinical events and health status data are gathered. This registry specifically evaluates adherence to ESC quality indicators in Italian clinical practice, including measures such as time to reperfusion and prescription of recommended medications at discharge. Participants will be monitored through regular collection of clinical data over the 12 months following enrollment. Researchers will assess adherence to multiple ESC quality indicators related to treatment and management of STEMI and NSTEMI patients, including evaluations of left ventricular function, lipid levels, and use of dual antiplatelet therapy and other medications. The study also tracks cardiovascular and non-cardiovascular events during follow-up to support quality improvement efforts. Participation involves consent and data collection without experimental treatments.

Researchers are collecting data on Tensi, a newly released medical device that uses transcutaneous-posterior tibial nerve stimulation TC-pTNS to manage overactive bladder OAB. Preliminary studies have indicated that this device has a favorable safety and efficacy profile. This registry study aims to gather information on how well the device works, its safety, and factors that may predict success in everyday clinical use over one year. Participants will use the Tensi device in a real-world clinical setting. The study will observe patients over a total period of one year to monitor their responses to the device. There are no additional treatment groups or placebo controls as this is an observational study focused on the devices use in current practice. Participants will be assessed at the start, 3 months, and 12 months to measure subjective improvement and quality of life. Patient-reported outcome measures PROMs will be collected at these time points along with voiding diaries. The study will monitor safety and adherence through these assessments over the year-long participation.